These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32663514)

  • 21. Reply to Fenton
    Bruni T; Lalvani A; Richeldi L
    Am J Respir Crit Care Med; 2020 Oct; 202(8):1192-1193. PubMed ID: 32790518
    [No Abstract]   [Full Text] [Related]  

  • 22. Dr. Favalli,
    Favalli EG; Agape E; Caporali R
    J Rheumatol; 2020 Oct; 47(10):1592. PubMed ID: 32482654
    [No Abstract]   [Full Text] [Related]  

  • 23. Reply to the letter of Singh and Singh in response to the article: "Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis" (Kumar et al.).
    Kumar A; Arora A; Sharma P; Anikhindi SA; Bansal N; Singla V; Khare S; Srivastava A
    Diabetes Metab Syndr; 2020; 14(5):1147-1148. PubMed ID: 32668400
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
    Ritchie AI; Singanayagam A
    Lancet; 2020 Apr; 395(10230):1111. PubMed ID: 32220278
    [No Abstract]   [Full Text] [Related]  

  • 25. Reply to Fekkar
    Bentvelsen RG; van Arkel ALE; Rijpstra TA; Belderbos HNA; van Wijngaarden P; Verweij PE
    Am J Respir Crit Care Med; 2020 Sep; 202(6):903-904. PubMed ID: 32687390
    [No Abstract]   [Full Text] [Related]  

  • 26. REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19.
    Piaserico S; Meneguzzo A; Messina F
    J Infect; 2020 Sep; 81(3):e37-e38. PubMed ID: 32610110
    [No Abstract]   [Full Text] [Related]  

  • 27. Reply Letter - COVID-19 (Novel Coronavirus 2019) - Recent trends.
    Kannan S; Shaik Syed Ali Pakeer P; Sheeza Ali A; Hemalatha K
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6482-6483. PubMed ID: 32633333
    [No Abstract]   [Full Text] [Related]  

  • 28. Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.).
    Singh AK; Gupta R; Misra A
    Diabetes Metab Syndr; 2020; 14(5):729. PubMed ID: 32473904
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatments for COVID-19: emerging drugs against the coronavirus - reply.
    Potì F
    Acta Biomed; 2020 Jun; 91(3):ahead of print. PubMed ID: 32921741
    [No Abstract]   [Full Text] [Related]  

  • 30. Targeting the immunology of coronavirus disease-19: synchronization creates symphony.
    Ahmed S; Anirvan P
    Rheumatol Int; 2020 Aug; 40(8):1343-1345. PubMed ID: 32533292
    [No Abstract]   [Full Text] [Related]  

  • 31. Reply to Modesto-Alapont
    Tobin MJ
    Am J Respir Crit Care Med; 2020 Jul; 202(2):300. PubMed ID: 32459507
    [No Abstract]   [Full Text] [Related]  

  • 32. Reply to Chand et al. regarding letter to the Editor regarding the article: 'Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic in India: A cohort analysis (Ghoshal et al.)'.
    Ghoshal S;
    Diabetes Metab Syndr; 2020; 14(5):1541. PubMed ID: 32947752
    [No Abstract]   [Full Text] [Related]  

  • 33. Gastrointestinal and liver involvement in patients with COVID-19 - Authors' reply.
    Qiu Y; He JS; Tan JY; Lin SN; Mao R
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):799-800. PubMed ID: 32818457
    [No Abstract]   [Full Text] [Related]  

  • 34. Endothelial barrier integrity in COVID-19-dependent hyperinflammation: does the protective facet of platelet function matter?
    Smeda M; Chlopicki S
    Cardiovasc Res; 2020 Aug; 116(10):e118-e121. PubMed ID: 32707576
    [No Abstract]   [Full Text] [Related]  

  • 35. Blood glucose levels and COVID-19. Reply to Sardu C, D'Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, Jüni P et al [letter].
    Cariou B; Hadjadj S; Wargny M; Pichelin M; Al-Salameh A; Allix I; Amadou C; Arnault G; Baudoux F; Bauduceau B; Borot S; Bourgeon-Ghittori M; Bourron O; Boutoille D; Cazenave-Roblot F; Chaumeil C; Cosson E; Coudol S; Darmon P; Disse E; Ducet-Boiffard A; Gaborit B; Joubert M; Kerlan V; Laviolle B; Marchand L; Meyer L; Potier L; Prevost G; Riveline JP; Robert R; Saulnier PJ; Sultan A; Thébaut JF; Thivolet C; Tramunt B; Vatier C; Roussel R; Gautier JF; Gourdy P;
    Diabetologia; 2020 Nov; 63(11):2491-2494. PubMed ID: 32816095
    [No Abstract]   [Full Text] [Related]  

  • 36. Reply to the Letter "COVID-19-Associated Encephalopathy and Cytokine-Mediated Neuroinflammation".
    Pilotto A; Padovani A;
    Ann Neurol; 2020 Oct; 88(4):861-862. PubMed ID: 32737995
    [No Abstract]   [Full Text] [Related]  

  • 37. Reply to "Coronavirus Disease 19 (COVID-19): Implications for Clinical Dental Care".
    Ather A; Patel B; Ruparel NB; Diogenes A; Hargreaves KM
    J Endod; 2020 Sep; 46(9):1342. PubMed ID: 32810475
    [No Abstract]   [Full Text] [Related]  

  • 38. Reply to: "Concerns Raised by Publication of Antonini et al., 'Outcome of Parkinson Disease Patients Affected by Covid-19'".
    Antonini A; Leta V; Teo J; Ray Chaudhuri K
    Mov Disord; 2020 Aug; 35(8):1298. PubMed ID: 32780513
    [No Abstract]   [Full Text] [Related]  

  • 39. The allergist/immunologist, the Janus gatekeeper of inflammation, COVID-19 and beyond.
    Bellanti JA; Settipane RA
    Allergy Asthma Proc; 2020 Nov; 41(6):395-396. PubMed ID: 33109305
    [No Abstract]   [Full Text] [Related]  

  • 40. In Reply to the Letter to the Editor Regarding "Neurological Impact of Coronavirus Disease (COVID-19): Practical Considerations for the Neuroscience Community".
    Scullen T; Mathkour M; Keen JR
    World Neurosurg; 2020 Oct; 142():535-536. PubMed ID: 32585382
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.